<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04247035</url>
  </required_header>
  <id_info>
    <org_study_id>Metastatic Breast Cancer</org_study_id>
    <nct_id>NCT04247035</nct_id>
  </id_info>
  <brief_title>Τreatment Standards and Outcomes of Patients With ER/PR Positive, HER2-negative Metastatic Breast Cancer</brief_title>
  <acronym>MBC</acronym>
  <official_title>Non-Interventional, Multi-center Registry of Recording of Treatment Standards and Outcomes of Patients With ER/PR Positive, HER2-negative Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hellenic Society of Medical Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hellenic Society of Medical Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      • To capture the treatment patterns and clinical characteristics of patients with ER/PR
      positive, HER2-negative MBC in Greece
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  To capture the treatment patterns and clinical characteristics of patients with ER/PR
           positive, HER2-negative MBC in Greece

        -  To evaluate the outcome of patients per treatment line (objective response, progression
           free survival, time to disease progression per line of therapy), overall survival

        -  To record adverse events per line of therapy

        -  To recording of the causes of treatment discontinuation per line of therapy
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 31, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Evaluation of the outcome per treatment line</measure>
    <time_frame>5 years</time_frame>
    <description>To evaluate the outcome of patients per treatment line (objective response, progression free survival, time to disease progression per line of therapy), overall survival</description>
  </primary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Women with histological confirmed ER/PR positive, HER2-negative MBC
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with histological confirmed ER/PR positive, HER2-negative MBC

          -  Age &gt;18 years old

          -  Patients initiating first or second line therapy for ER/PR positive, HER2-negative MBC

          -  Adequate hematologic, renal and hepatic function

          -  Signed informed consent (ICF)

        Exclusion Criteria:

          -  Active malignancy other than MBC

          -  Active infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ioannis Boukovinas, Dr /Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>HeSMO</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sofia Agelaki, prof</last_name>
    <phone>+302106457971</phone>
    <email>agelakisofia@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kalliopi Sarikaki</last_name>
    <phone>+302106457971</phone>
    <email>psarikaki@hesmo.gr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hellenic Society of Medical Oncology</name>
      <address>
        <city>Athens</city>
        <zip>11475</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kalliopi Sarikaki, SC</last_name>
      <phone>+302106457971</phone>
      <email>psarikaki@hesmo.gr</email>
    </contact>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 24, 2020</study_first_submitted>
  <study_first_submitted_qc>January 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2020</study_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

